| Dr Andrei Popescu, MD, PHD | |
|
1761 Beall Ave, Wooster Community Hospital, Wooster, OH 44691-2342 | |
| (330) 263-8169 | |
| Not Available |
| Full Name | Dr Andrei Popescu |
|---|---|
| Gender | Male |
| Speciality | Hospitalist |
| Experience | 26 Years |
| Location | 1761 Beall Ave, Wooster, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174728505 | NPI | - | NPPES |
| 2836748 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 35-090345 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Firelands Regional Medical Center | Sandusky, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| North Coast Professional Company, Llc | 6305810201 | 92 |
News Archive
SEBM is pleased to announce the winners of the Best Paper Awards for articles published in the journal Experimental Biology and Medicine during 2011. SEBM recognizes the best paper annually in each of 3 categories: Clinical/Preclinical and Translation Research, Experimental Biology, and Interdisciplinary Research.
The recent achievements in studies looking at treatment as prevention "were only made possible by the partnership between publicly funded scientists and private drug companies," Ward Cates, president of research at FHI; Salim Abdool Karim, director of the Centre for the AIDS Program of Research in South Africa; and Myron Cohen, director of the UNC Division of Infectious Disease and the UNC Institute for Global Health and Infectious Disease, write in an opinion piece in the Huffington Post.
Pennsylvania begins enrolling residents in its new high-risk insurance program. Elsewhere, Wisconsin trims its Medicaid program and states regulate the use of medical marijuana.
Proteon Therapeutics, Inc., has initiated a Phase 1/2 human clinical study of its lead product, PRT-201, in end-stage renal disease (ESRD) patients undergoing surgery for arteriovenous graft (AVG) creation. The AVG study represents Proteon's second human clinical study in hemodialysis patients, previously announcing the initiation of a Phase 1/2 study of PRT-201 in ESRD patients undergoing surgery for arteriovenous fistula (AVF) creation earlier this year.
› Verified 6 days ago
| Entity Name | Inpatient Medical Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093756314 PECOS PAC ID: 6406753045 Enrollment ID: O20031212000790 |
News Archive
SEBM is pleased to announce the winners of the Best Paper Awards for articles published in the journal Experimental Biology and Medicine during 2011. SEBM recognizes the best paper annually in each of 3 categories: Clinical/Preclinical and Translation Research, Experimental Biology, and Interdisciplinary Research.
The recent achievements in studies looking at treatment as prevention "were only made possible by the partnership between publicly funded scientists and private drug companies," Ward Cates, president of research at FHI; Salim Abdool Karim, director of the Centre for the AIDS Program of Research in South Africa; and Myron Cohen, director of the UNC Division of Infectious Disease and the UNC Institute for Global Health and Infectious Disease, write in an opinion piece in the Huffington Post.
Pennsylvania begins enrolling residents in its new high-risk insurance program. Elsewhere, Wisconsin trims its Medicaid program and states regulate the use of medical marijuana.
Proteon Therapeutics, Inc., has initiated a Phase 1/2 human clinical study of its lead product, PRT-201, in end-stage renal disease (ESRD) patients undergoing surgery for arteriovenous graft (AVG) creation. The AVG study represents Proteon's second human clinical study in hemodialysis patients, previously announcing the initiation of a Phase 1/2 study of PRT-201 in ESRD patients undergoing surgery for arteriovenous fistula (AVF) creation earlier this year.
› Verified 6 days ago
| Entity Name | Community Hospitalist Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538236872 PECOS PAC ID: 5496648123 Enrollment ID: O20040205000697 |
News Archive
SEBM is pleased to announce the winners of the Best Paper Awards for articles published in the journal Experimental Biology and Medicine during 2011. SEBM recognizes the best paper annually in each of 3 categories: Clinical/Preclinical and Translation Research, Experimental Biology, and Interdisciplinary Research.
The recent achievements in studies looking at treatment as prevention "were only made possible by the partnership between publicly funded scientists and private drug companies," Ward Cates, president of research at FHI; Salim Abdool Karim, director of the Centre for the AIDS Program of Research in South Africa; and Myron Cohen, director of the UNC Division of Infectious Disease and the UNC Institute for Global Health and Infectious Disease, write in an opinion piece in the Huffington Post.
Pennsylvania begins enrolling residents in its new high-risk insurance program. Elsewhere, Wisconsin trims its Medicaid program and states regulate the use of medical marijuana.
Proteon Therapeutics, Inc., has initiated a Phase 1/2 human clinical study of its lead product, PRT-201, in end-stage renal disease (ESRD) patients undergoing surgery for arteriovenous graft (AVG) creation. The AVG study represents Proteon's second human clinical study in hemodialysis patients, previously announcing the initiation of a Phase 1/2 study of PRT-201 in ESRD patients undergoing surgery for arteriovenous fistula (AVF) creation earlier this year.
› Verified 6 days ago
| Entity Name | Ashtabula County Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942247143 PECOS PAC ID: 2668465600 Enrollment ID: O20040406000897 |
News Archive
SEBM is pleased to announce the winners of the Best Paper Awards for articles published in the journal Experimental Biology and Medicine during 2011. SEBM recognizes the best paper annually in each of 3 categories: Clinical/Preclinical and Translation Research, Experimental Biology, and Interdisciplinary Research.
The recent achievements in studies looking at treatment as prevention "were only made possible by the partnership between publicly funded scientists and private drug companies," Ward Cates, president of research at FHI; Salim Abdool Karim, director of the Centre for the AIDS Program of Research in South Africa; and Myron Cohen, director of the UNC Division of Infectious Disease and the UNC Institute for Global Health and Infectious Disease, write in an opinion piece in the Huffington Post.
Pennsylvania begins enrolling residents in its new high-risk insurance program. Elsewhere, Wisconsin trims its Medicaid program and states regulate the use of medical marijuana.
Proteon Therapeutics, Inc., has initiated a Phase 1/2 human clinical study of its lead product, PRT-201, in end-stage renal disease (ESRD) patients undergoing surgery for arteriovenous graft (AVG) creation. The AVG study represents Proteon's second human clinical study in hemodialysis patients, previously announcing the initiation of a Phase 1/2 study of PRT-201 in ESRD patients undergoing surgery for arteriovenous fistula (AVF) creation earlier this year.
› Verified 6 days ago
| Entity Name | North Coast Professional Company, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881648210 PECOS PAC ID: 6305810201 Enrollment ID: O20040825001179 |
News Archive
SEBM is pleased to announce the winners of the Best Paper Awards for articles published in the journal Experimental Biology and Medicine during 2011. SEBM recognizes the best paper annually in each of 3 categories: Clinical/Preclinical and Translation Research, Experimental Biology, and Interdisciplinary Research.
The recent achievements in studies looking at treatment as prevention "were only made possible by the partnership between publicly funded scientists and private drug companies," Ward Cates, president of research at FHI; Salim Abdool Karim, director of the Centre for the AIDS Program of Research in South Africa; and Myron Cohen, director of the UNC Division of Infectious Disease and the UNC Institute for Global Health and Infectious Disease, write in an opinion piece in the Huffington Post.
Pennsylvania begins enrolling residents in its new high-risk insurance program. Elsewhere, Wisconsin trims its Medicaid program and states regulate the use of medical marijuana.
Proteon Therapeutics, Inc., has initiated a Phase 1/2 human clinical study of its lead product, PRT-201, in end-stage renal disease (ESRD) patients undergoing surgery for arteriovenous graft (AVG) creation. The AVG study represents Proteon's second human clinical study in hemodialysis patients, previously announcing the initiation of a Phase 1/2 study of PRT-201 in ESRD patients undergoing surgery for arteriovenous fistula (AVF) creation earlier this year.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Andrei Popescu, MD, PHD 14196 Catherine Ct, North Royalton, OH 44133-5257 Ph: (216) 212-5601 | Dr Andrei Popescu, MD, PHD 1761 Beall Ave, Wooster Community Hospital, Wooster, OH 44691-2342 Ph: (330) 263-8169 |
News Archive
SEBM is pleased to announce the winners of the Best Paper Awards for articles published in the journal Experimental Biology and Medicine during 2011. SEBM recognizes the best paper annually in each of 3 categories: Clinical/Preclinical and Translation Research, Experimental Biology, and Interdisciplinary Research.
The recent achievements in studies looking at treatment as prevention "were only made possible by the partnership between publicly funded scientists and private drug companies," Ward Cates, president of research at FHI; Salim Abdool Karim, director of the Centre for the AIDS Program of Research in South Africa; and Myron Cohen, director of the UNC Division of Infectious Disease and the UNC Institute for Global Health and Infectious Disease, write in an opinion piece in the Huffington Post.
Pennsylvania begins enrolling residents in its new high-risk insurance program. Elsewhere, Wisconsin trims its Medicaid program and states regulate the use of medical marijuana.
Proteon Therapeutics, Inc., has initiated a Phase 1/2 human clinical study of its lead product, PRT-201, in end-stage renal disease (ESRD) patients undergoing surgery for arteriovenous graft (AVG) creation. The AVG study represents Proteon's second human clinical study in hemodialysis patients, previously announcing the initiation of a Phase 1/2 study of PRT-201 in ESRD patients undergoing surgery for arteriovenous fistula (AVF) creation earlier this year.
› Verified 6 days ago
Dr. Ghasem Ashelfah, M.D Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1761 Beall Ave, Wooster, OH 44691 Phone: 330-263-8428 Fax: 330-263-8190 | |
Alexander Mosteller, DO Hospitalist Medicare: Medicare Enrolled Practice Location: 1761 Beall Ave, Wooster, OH 44691 Phone: 330-263-8326 | |
Dr. Tiffany Sue Morris, M.D. Hospitalist Medicare: Not Enrolled in Medicare Practice Location: 1761 Beall Ave, Wooster, OH 44691 Phone: 330-465-8332 |